PPARG and Alzheimer disease: For example, full PPARγ agonists Pio and rosiglitazone (rosi) improved cognition in the PS1-KI (human presenilin-1 M146V knock-in mouse) mouse model of AD following a 9-month treatment (20 mg/kg) [10].